Clinical Trial Update: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2/3 study evaluating a four-drug combination (margetuximab, retifanlimab, tebotelimab, and chemothe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Margetuximab (margetuximab)
• Retifanlimab (retifanlimab)
• Tebotelimab (tebotelimab)

Snippet

Sponsor: MacroGenics | Conditions: Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-04-22